Original Research

A Multipronged Approach to Decrease the Risk of Clostridium difficile Infection at a Community Hospital and Long-Term Care Facility

Journal of Clinical Outcomes Management. 2015 September;22(9)

Author(s):

Bridget Olson, RPh

Ronald A. Floyd, PharmD, MS

John Howard, PharmD

Tarek Hassanein, MD

Kenneth Warm, MD

Roger Oen, MD, MPH

References

1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. http://www.cdc.gov/drugresistance/threat-report-2013/index.html.

2. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015;372:825–34.

3. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005;173:1037–42.

4. Warren JW, Palumbo FB, Fitterman L, Speedie SM. Incidence and characteristics of antibiotic use in aged nursing home patients. J Am Geriatr Soc 1991;39:963–72.

5. Linsky A, Gupta K, Lawler E, et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010;170:772–8.

6. Dial S, Delaney JA, Barkun AN, Sulssa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294:2989–95.

7. Howell M, Novack V, Grgurich P, et.al. Iatrogenic gastric acid suppression and the risk if nosocomial Clostridium difficile infection. Arch Intern Med 2010;170:784–90.

8. Radulovic Z, Petrovic T, Bulajic S. Antibiotic susceptibility of probiotic bacteria. In Pana M, editor. Antibiotic resistant bacteria: a continuous challenge in the new millennium. Rijeka, Croatia: InTech; 2012.

9. Goldenberg JZ, Ma SS, Saxton JD, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2013;5:CD006095.

10. Johnston BC, Ma SY, Goldenberg JZ, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea. Ann Intern Med 2012;157:878–88.

11. Blondeau JM. What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea? J Antimicrob Chemother 2009;63:203–37.

12. Elliott B, Chang BJ, Golledge CL et al. Clostridium difficile-associated diarrhoea. Intern Med J 2007;37:561–8.

13. Stone, ND, Ashraf, MS et al. Surveillance definitions of infections in long-term care facilities: revisiting the McGeer criteria. Infect Control Hosp Epidemiol 2012;33:965–77.

14. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012;107:1001–10.

15. Gao XW, Mubasher M, Fang CY, et al. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010;105:1636-41.

16. Maziade PJ, Andriessen JA, Pereira P, et.al. Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital. Curr Med Res Opin 2013;29:1341–7.

17. Islam, J, Cohen J, Rajkumar C, Llewelyn M. Probiotics for the prevention and treatment of Clostridium difficile in older patients. Age Ageing 2012;41:706–11.

18. Hickson M, D’Souza AL, Muthu N, et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007;335:80.

19. Allen S J, Wareham K, Wang, D, et.al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomized, double-blind, placebo-controlled, multi-centre trial. Lancet 2013;382:1249–57.

From Sharp HealthCare, San Diego, CA.

Abstract

Objective: To examine the relationship between the rate of Clostridium difficile infections (CDI) and implementation of 3 interventions aimed at preserving the fecal microbiome: (1) reduction of antimicrobial pressure; (2) reduction in intensity of gastrointestinal prophylaxis with proton-pump inhibitors (PPIs); and (3) expansion of probiotic therapy.
Methods: We conducted a retrospective analysis of all inpatients with CDI between January 2009 and December 2013 receiving care at our community hospital and associated long-term care (LTC) facility. We used interrupted time series analysis to assess CDI rates during the implementation phase (2008–2010) and the postimplementation phase (2011–2013).
Results: A reduction in the rate of health care facility–associated CDIs was seen. The mean number of cases per 10,000 patient days fell from 11.9 to 3.6 in acute care and 6.1 to 1.1 in LTC. Recurrence rates decreased from 64% in 2009 to 16% by 2014. The likelihood of CDI recurring was 3 times higher in those exposed to PPI and 0.35 times less likely in those who received probiotics with their initial CDI therapy.
Conclusion: The risk of CDI incidence and recurrence was significantly reduced in our inpatients, with recurrent CDI associated with PPI use, multiple antibiotic courses, and lack of probiotics. We attribute our success to the combined effect of intensified antibiotic stewardship, reduced PPI use, and expanded probiotic use.

Clostridium difficile is classified as an urgent public health threat by the Centers for Disease Control and Prevention [1]. A recent study by the CDC found that it caused more than 400,000 infections in the United States in 2011, leading to over 29,000 deaths [2]. The costs of treating CDI are substantial and recurrences are common. While rates for many health care–associated infections are declining, C. difficile infection (CDI) rates remain at historically high levels [1] with the elderly at greatest risk for infection and mortality from the illness [3].

CDIs can be prevented. A principal recommendation for preventing CDIs is improving antibiotic use. Antibiotic use increases the risk for developing CDI by disrupting the colonic microbiome. Hospitalized and long-term care (LTC) patients are frequently prescribed antibiotics, but studies indicate that much of this use is inappropriate [4]. Antimicrobial stewardship has been shown to be effective in reducing CDI rates. Other infection prevention measures commonly employed to decrease the risk of hospital-onset CDI include monitoring of hand hygiene compliance using soap and water, terminal cleaning with bleach products of rooms occupied by patients with CDI, and daily cleaning of highly touched areas. At our institution, patients identified with CDI are placed on contact precautions until they have been adequately treated and have had resolution of diarrhea for 48 hours.

In addition to preventing CDI transmission through antimicrobial stewardship, attention is being paid to the possibility that restricting PPI use may help in preventing CDI. The increasing utilization of proton-pump inhibitors (PPIs) in recent years has coincided with the trend of increasing CDI rates. Although C. difficile spores are acid-resistant, vegetative forms are easily affected by acidity. Several studies have shown the association of acid suppression and greater susceptibility of acquiring CDI or recurrences [5–7]. Elevated gastric pH by PPIs facilitates the growth of potentially pathogenic upper and lower gastrointestinal (GI) tract flora, including the conversion of C. difficile from spore to vegetative form in the upper GI tract [5,8].